
Fwd: :Request for correction-Br. J. Cancer 2014; 110(6): 1645-1654

rajvir dahiya <rdahiya@gmail.com>
To: Ellie Kincaid <kincaid.ellie@gmail.com>, rajvir dahiya <rdahiya@gmail.com>

Wed, Aug 16, 2023 at 4:52 PM

Dear Ellie

Thank you for contacting me regarding our paper Brit. J. Cancer 2014; 110(6): 1645-1654.

On May 18th 2018, Dr. Hiroshi Hirata voluntarily proposed to replace Figure 4D as a correction and the Editor-in-chief and Scientific Publications Manager of Brit. J. Cancer agreed to go ahead with a correction of this figure.

Now on August 16th 2023 (after 5 years), the VA / UCSF investigation committee does not agree with this correction and forces Brit. J. Cancer to write this statement.

Please feel free to contact me if you need further information

Best regards

Rajvir Dahiya
Professor Emeritus
UCSF, San Francisco

----- Forwarded message -----

From: **Maria Hodges** <Maria.Hodges@cancer.org.uk>
Date: Fri, May 18, 2018 at 8:56 AM
Subject: :Request for correction-Br. J. Cancer 2014; 110(6): 1645-1654
To: hiroshi_ucsf@yahoo.co.jp <hiroshi_ucsf@yahoo.co.jp>
Cc: Raj Dahiya <rdahiya@gmail.com>, bjc <BJC@cancer.org.uk>

Dear Hiroshi,

Thank you for the clarification. Adrian Harris has reviewed your emails and would like to go ahead with a correction for the migration assay.

Please see attached the draft correction. Please let me know if any changes are required.

Best wishes

Maria

Maria Hodges PhDScientific Publications Manager
British Journal of Cancer

Cancer Research UK

Tel | 0203 469 6076



From: hiroshi_ucsf@yahoo.co.jp [mailto:hiroshi_ucsf@yahoo.co.jp]
Sent: 16 May 2018 13:38
To: Maria Hodges <Maria.Hodges@cancer.org.uk>

Cc: Raj Dahiya <rdahiya@gmail.com>
Subject: Re: RE: Request for correction-Br. J. Cancer 2014; 110(6): 1645-1654

Dear Maria

I am so sorry to be late for Emailing to you.

I would answer on two points:

1. Were the loading control blots from the same gel as the experimental blots shown?

Answer is Yes.

2. How many cut up gels is the figure from?

Answer is 5.

The gels were transferred to the membrane and then the membrane was cut for antibody staining. One is for control and four are for different antibodies.

Thank you so much.

Best wishes

Hiroshi

----- Original Message -----

From: Maria Hodges <Maria.Hodges@cancer.org.uk>
To: "hiroshi_ucsf@yahoo.co.jp" <hiroshi_ucsf@yahoo.co.jp>
Cc: bjc <BJC@cancer.org.uk>; "rdahiya@gmail.com" <rdahiya@gmail.com>
Date: 2018/5/16, Wed 00:20
Subject: RE: RE: Request for correction-Br. J. Cancer 2014; 110(6): 1645-1654

Dear Hiroshi,

Prof Adrian Harris, the Editor in Chief of *BJC*, has read your explanation and examined the gels.

He would like clarification on two points:

1. Were the loading control blots from the same gel as the experimental blots shown?
2. How many cut up gels is the figure from?

Best wishes

Maria

From: hiroshi_ucsf@yahoo.co.jp <hiroshi_ucsf@yahoo.co.jp>
Sent: 12 May 2018 04:51
To: bjc
Cc: Raj Dahiya
Subject: Re: RE: Request for correction-Br. J. Cancer 2014; 110(6): 1645-1654

Dear Maria

Thank you so much for your response.

Regarding the test antibodies (sFRP1 and Smad4), after transfer the protein from gel to the membrane,

I had cut the membrane. Antibody staining was done for small membrane. The small one is original. Attached original WB data is original.

In addition, we used two gels for Western blot for control and test antibodies, separately.

First, I performed WB for control using 4 samples (PC3-NC inhibitor, DU145-NC, inhibitor)

to look at whether the blotting technique was fine or not.

Then samples for test antibodies were loaded using new gel and done as mentioned above.

WB condition was maybe different. So there may appear to be differences in the shape and size.

Thank you so much again.

Best regards,

Hiroshi

----- Original Message -----

From: bjc <BJC@cancer.org.uk>
To: "hiroshi.ucsf@yahoo.co.jp" <hiroshi.ucsf@yahoo.co.jp>; "rdahiya@gmail.com" <rdahiya@gmail.com>
Cc: Maria Hodges <Maria.Hodges@cancer.org.uk>; bjc <BJC@cancer.org.uk>
Date: 2018/5/11, Fri 22:57
Subject: RE: RE: Request for correction-Br. J. Cancer 2014; 110(6): 1645-1654

Dear Hiroshi,

Thank you for your email and I'm sorry for the delay in replying to you.

Thank you for providing the original PC3 blots for the test antibodies anti-sFRP1 and anti-SMAD4. On looking at these blots alongside the loading control, the beta tubulin loading control for the four conditions (PC3 and DO-145, +/- miR) is presented as a single blot, whereas the test antibodies are presented as separate blots for the two cell lines. In addition, there appears to be differences in the shape and size of the bands between the loading control and the test antibodies. Please could you check that this is the correct loading control and if it has been inadvertently swapped please could you provide the correct one?

Best wishes

Maria

Maria Hodges PhD

Scientific Publications Manager

British Journal of Cancer

From: hiroshi.ucsf@yahoo.co.jp [mailto:hiroshi.ucsf@yahoo.co.jp]
Sent: 08 May 2018 06:49
To: bjc <BJC@cancer.org.uk>
Cc: Raj Dahiya <rdahiya@gmail.com>
Subject: Re: RE: Request for correction-Br. J. Cancer 2014; 110(6): 1645-1654

Dear Maria

I got Email from Dr Dahiya to contact you about correction.

How should we do for our correction?


Best regards,

Hiroshi

NOTICE AND DISCLAIMER This e-mail (including any attachments) is intended for the above-named person(s). If you are not the intended recipient, notify the sender immediately, delete this email from your system and do not disclose or use for any purpose. We may monitor all incoming and outgoing emails in line with current legislation. We have taken steps to ensure that this email and attachments are free from any virus, but it remains your responsibility to ensure that viruses do not adversely affect you. Cancer Research UK Registered charity in England and Wales (1089464), Scotland (SC041666) and the Isle of Man (1103) A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered Office Address: Angel Building, [407 St John Street, London EC1V 4AD](#).

NOTICE AND DISCLAIMER This e-mail (including any attachments) is intended for the above-named person(s). If you are not the intended recipient, notify the sender immediately, delete this email from your system and do not disclose or use for any purpose. We may monitor all incoming and outgoing emails in line with current legislation. We have taken steps to ensure that this email and attachments are free from any virus, but it remains your responsibility to ensure that viruses do not adversely affect you. Cancer Research UK Registered charity in England and Wales (1089464), Scotland (SC041666) and the Isle of Man (1103) A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered Office Address: Angel Building, [407 St John Street, London EC1V 4AD](#).

NOTICE AND DISCLAIMER This e-mail (including any attachments) is intended for the above-named person(s). If you are not the intended recipient, notify the sender immediately, delete this email from your system and do not disclose or use for any purpose. We may monitor all incoming and outgoing emails in line with current legislation. We have taken steps to ensure that this email and attachments are free from any virus, but it remains your responsibility to ensure that viruses do not adversely affect you. Cancer Research UK Registered charity in England and Wales (1089464), Scotland (SC041666) and the Isle of Man (1103) A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered Office Address: Angel Building, [407 St John Street, London EC1V 4AD](#).

 MD-2013-3858 - Dahiya.docx
714K